Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights
Provided By GlobeNewswire
Last update: Nov 7, 2024
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the third quarter ended September 30, 2024.
Read more at globenewswire.com
